羚锐品牌怎么样 申请店铺

我要投票 羚锐在中草药行业中的票数:94 更新时间:2025-02-05
羚锐是哪个国家的品牌?「羚锐」是 河南羚锐制药股份有限公司 旗下著名品牌。该品牌发源于河南,由创始人熊伟在1999-04-18期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
羚锐怎么样

河南羚锐制药股份有限公司始创于1992年6月,由河南省信阳羚羊山制药厂和香港锐星企业公司合资组建而成,2000年10月成功上市,成长为国内知名制药企业。目前,公司在北京、上海、武汉、郑州、信阳等地控股、参股十余家企业,拥有多个科研、生产基地,其中羚锐新县生态工业园为国内最大的橡胶膏剂药品生产基地,羚锐信阳科技园为国内先进的大型口服药生产基地,建立在北京的羚锐药物研究院和羚锐伟业科技有限公司为公司的科技研发基地。公司资产总额10亿元,年创利税逾亿元,已成为当地经济发展的支柱企业。

公司拥有橡胶膏剂、片剂、胶囊剂、颗粒剂、酊剂等十大剂型百余种产品,其中包括通络祛痛膏(骨质增生一贴灵)、培元通脑胶囊、丹鹿通督片、胃疼宁片、参芪降糖胶囊等独家拥有知识产权的产品及国家中药保护品种和国家医保药品。公司的所有产品剂型及其生产车间均通过国家GMP认证,质量标准实现了与国际接轨。

公司先后被评为“全国中药工业50强企业”、“全国中药系统先进集体”、“全国医药优秀企业”、“国家知识产权试点单位”,1999年和2005年先后两次被中央文明委表彰为“全国精神文明建设工作先进单位”,2001年被国家科技部认定为“国家火炬计划重点高新技术企业”,公司党委被中组部命名表彰为“全国先进基层党组织”;2002年“羚锐”商标被国家工商行政管理总局认定为“中国驰名商标”,成为国内橡胶膏剂药业中首件驰名商标。藉此,羚锐制药被业界誉为“中国橡胶膏剂药业第一品牌”。

浴火淬炼,十数年磨剑,羚锐始崛起,并稳健前进。

以“诚信立业,造福人类”为本,弘“团结、进取、创新、奉献”之志,坚持创新,实施人才兴企战略,以高新技术与传统药理、现代理念与先进文化完美融合,构筑企业平台,共享发展资源,我们将进一步提升核心竞争力,着力打造医药的优秀企业,成就百年基业。

Henan Lingrui Pharmaceutical Co., Ltd. was founded in June 1992 by Henan Xinyang lingyangshan pharmaceutical factory and Hong Kong Ruixing enterprise company. It was successfully listed in October 2000 and grew into a well-known pharmaceutical enterprise in China. At present, the company holds and shares more than ten enterprises in Beijing, Shanghai, Wuhan, Zhengzhou, Xinyang and other places, and has many scientific research and production bases. Among them, Lingrui new County Ecological Industrial Park is the largest rubber paste drug production base in China, Lingrui Xinyang science and technology park is the advanced large oral drug production base in China, and Lingrui Drug Research Institute and Lingrui Weiye science and technology established in Beijing Ltd. is the R & D base of the company. The company has a total assets of 1 billion yuan and an annual income tax of more than 100 million yuan, which has become a pillar enterprise of local economic development. The company has more than 100 kinds of products in ten dosage forms including rubber plaster, tablet, capsule, granule and tincture, including Tongluo Qutong plaster (hyperosteogeny Yitieling), Peiyuan Tongnao capsule, Danlu Tongdu tablet, Weitongning tablet, Shenqi Jiangtang Capsule and other products with exclusive intellectual property rights, national traditional Chinese medicine protection varieties and national medical insurance drugs. All the dosage forms and production workshops of the company have passed the national GMP certification, and the quality standards have been in line with the international standards. The company has been awarded as "top 50 enterprises of Chinese medicine industry", "advanced collective of Chinese medicine system", "excellent enterprise of Chinese medicine" and "pilot unit of national intellectual property". In 1999 and 2005, the company was awarded as "advanced unit of national spiritual civilization construction" by the central civilization Committee. In 2001, the company was recognized as "key high and new technology of national Torch Plan" by the Ministry of science and technology In 2002, "Lingrui" trademark was recognized as "China's well-known trademark" by the State Administration for Industry and commerce, and became the first well-known trademark in the domestic rubber paste pharmaceutical industry. Therefore, Lingrui pharmaceutical is known as "the first brand of Chinese rubber paste pharmaceutical industry". Bath fire quenching, more than ten years of sword sharpening, antelope sharp began to rise, and steady progress. Based on the principle of "building a business in good faith and benefiting mankind", we will carry out the strategy of "uniting, enterprising, innovating and dedicating", persist in innovation, carry out the strategy of developing an enterprise with talents, perfectly integrate high and new technology with traditional pharmacology, modern concept and advanced culture, build an enterprise platform and share development resources. We will further enhance our core competitiveness and strive to build an excellent enterprise in medicine, Achieve a century long foundation.

本文链接: https://brand.waitui.com/e8963bc9e.html 联系电话:03762973599

千城特选小程序码

7×24h 快讯

美股大型科技股盘前多数下跌,谷歌跌超7%

36氪获悉,美股大型科技股盘前多数下跌,截至发稿,谷歌跌超7%,亚马逊、苹果跌超1%,特斯拉跌0.92%,微软跌0.36%,Meta跌0.35%,奈飞跌0.14%;英伟达涨近1%。

15分钟前

热门中概股美股盘前多数走弱,拼多多跌超7%

36氪获悉,热门中概股美股盘前多数走弱,截至发稿,拼多多跌超7%,理想汽车、微博跌超3%,阿里巴巴、京东、百度、蔚来跌超2%,小鹏汽车、爱奇艺跌超1%;B站涨超1%。

15分钟前

君实生物:AWT020注射用无菌粉末临床试验申请获批

36氪获悉,君实生物公告,近日,公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》,AWT020注射用无菌粉末(项目代号“JS213”)的临床试验申请获得批准。JS213是PD-1和白细胞介素-2双功能性抗体融合蛋白,主要用于晚期恶性肿瘤的治疗。

15分钟前

渣打集团任命Maria Ramos接替韦浩思担任集团主席

2月4日,渣打集团董事会宣布,鉴于韦浩思(José Viñals)已接近他服务满9年的任期,已任命Maria Ramos(65岁)接替韦浩思担任集团主席。待取得监管批准后,Maria将于公司在2025年5月8日举行的2025年股东周年大会后履新,而韦浩思届时将自董事会退任。(界面)

15分钟前

三六零:公司暂未向DeepSeek提供任何服务

36氪获悉,三六零公告,公司股票于2025年1月24日、1月27日、2月5日连续三个交易日内收盘价格涨幅偏离值累计超过20%,属于股票交易异常波动情形。经自查,公司注意到相关平台将公司股票纳入DeepSeek概念股。公司就相关事项澄清说明如下:在DeepSeek基于MIT开源协议的生态环境下,公司旗下的部分产品进行了DeepSeek的接入与本地化部署;公司暂未向DeepSeek提供任何服务。除上述事项外,公司未发现其他可能对公司股票交易价格产生较大影响的、需要公司澄清或回应的媒体报道或市场传闻

15分钟前

本页详细列出关于前列康的品牌信息,含品牌所属公司介绍,前列康所处行业的品牌地位及优势。
咨询